Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of ESK-001 in Adults With Systemic Lupus Erythematosus
2022-502105-15-00Phase 2Authorised
- Sponsor
- Alumis Inc.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing ESK-001 with Placebo (2 arms). Primary endpoint: Composite primary efficacy endpoint. Planned start Oct 2023; status: authorised.
02
Drugs
envudeucitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2022-502105-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502105-15-00.